ONCOS 102

Drug Profile

ONCOS 102

Alternative Names: Ad5/3-D24-GMCSF; CGTG-102; ONCOS-102

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Oncos Therapeutics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Ovarian cancer; Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mesothelioma
  • Phase I Malignant melanoma; Ovarian cancer; Soft tissue sarcoma
  • Preclinical Prostate cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 Feb 2017 Targovax plans proof-of-concept trial for Malignant melanoma
  • 21 Nov 2016 Targovax and MedImmune plan a phase I/II trial for Cancer (Combination therapy, Second-line therapy or greater) in USA (NCT02963831)
  • 14 Oct 2016 Targovax suspends a phase-I/II trial in Mesothelioma (Combination therapy, Inoperable/Unresectable) in Spain (EudraCT2015-005143-13) prior to October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top